Combined protection of vaccination and nirmatrelvir-ritonavir against hospitalization in adults with COVID-19

Melisa M Shah; Brendan Joyce; Ian D Plumb; Sam Sahakian; Leora R Feldstein; Eric Barkley; Mason Paccione; Joseph Deckert; Danessa Sandmann; Melissa Briggs Hagen; Jacqueline L Gerhart

doi:10.1093/cid/ciae105

Combined protection of vaccination and nirmatrelvir-ritonavir against hospitalization in adults with COVID-19

Clin Infect Dis. 2024 Feb 27:ciae105. doi: 10.1093/cid/ciae105. Online ahead of print.

Affiliations

¹ Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, CDC.
² Epic Research, Epic Systems Corporation, Verona, Wisconsin, USA.

PMID: 38411622
DOI: 10.1093/cid/ciae105

Abstract

Among U.S. adults at risk for severe COVID-19 in Epic Cosmos, the lowest rate of hospitalization was among those receiving three or more mRNA vaccine doses and nirmatrelvir-ritonavir (aHR 0.22, 95%CI: 0.19-0.24). Adults who are at high-risk of severe COVID-19 disease, including vaccinated persons, should be considered for antiviral treatment.

Keywords: SARS-CoV-2; covid-19; nirmatrelvir-ritonavir; vaccination.